Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Prime Medicine (PRME) Preferred Stock Liabilities (2021 - 2022)

Historic Preferred Stock Liabilities for Prime Medicine (PRME) over the last 2 years, with Q3 2022 value amounting to $395.8 million.

  • Prime Medicine's Preferred Stock Liabilities rose 9825.39% to $395.8 million in Q3 2022 from the same period last year, while for Sep 2022 it was $395.8 million, marking a year-over-year increase of 9825.39%. This contributed to the annual value of $395.8 million for FY2021, which is 117119.73% up from last year.
  • According to the latest figures from Q3 2022, Prime Medicine's Preferred Stock Liabilities is $395.8 million, which was up 9825.39% from $395.8 million recorded in Q4 2021.
  • In the past 5 years, Prime Medicine's Preferred Stock Liabilities ranged from a high of $395.8 million in Q4 2021 and a low of $199.6 million during Q3 2021